血管紧张素Ⅱ1型受体自身抗体与子痫前期
Association between Autoantibodies against Angiotension Ⅱ Type 1 Receptor and Pre-Eclampsia (Review)

作者: 马桂伶 , 张 麟 :首都医科大学附属北京朝阳医院心脏中心,北京; 李艳芳 :首都医科大学附属北京朝阳医院妇产科,北京;

关键词: 子痫前期血管紧张素Ⅱ1型受体自身抗体 Pre-Eclampsia Angiotension Ⅱ Type 1 Receptor Autoantibody

摘要:

子痫前期以高血压、蛋白尿为特征,并伴有全身多脏器的损害。其发病率为3%~5%,是母婴发病率及死亡率较高的主要原因。重症患者只有及时终止妊娠才可阻止孕妇和胎儿情况的进一步恶化。目前子痫前期的发病机制尚未研究清楚。近来,多项研究证实子痫前期孕妇血清中存在抗血管紧张素1型受体自身抗体,通过专一识别细胞外第二环功能表位肽段发挥作用。本文旨在综述这些最新进展。

Abstract:

Pre-eclampsia is a serious hypertensive disorder of pregnancy that affects 3% - 5% of pregnancies, and remains the leading cause of maternal and neonatal mortalities and morbidities in the world. It is a multisystemic disease with the common features of hypertension and proteinuria. In serious cases, termination of pregnancy is the only available option to prevent further deterioration of the fetus and mother. To date, the factors triggering, and the underlying mechanisms, responsible for the pathogenesis of pre-eclampsia remain unknown. Recently, numerous studies have shown that pre-eclamptic women possess autoantibody against angiotensin type 1 receptor, which bind to and activate the receptor provoking biological responses relevant to the pathogenesis of pre-eclampsia. The current paper is to review the most recent development.



Abstract:



Abstract:

文章引用: 马桂伶 , 李艳芳 , 张 麟 (2013) 血管紧张素Ⅱ1型受体自身抗体与子痫前期。 临床医学进展, 3, 1-4. doi: 10.12677/ACM.2013.31001

参考文献

[1] J. A. Hutcheon, S. Lisonkova and K. S. Joseph. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Practice & Research Clinical Obstetrics and Gynaecology, 2011, 25(4): 391-403.

[2] M. Hanssens, M. J. Keirse, B. Spitz and F. A. Van Assche. Measurement of individual plasma Angiotensins in normal pregnaney and pregnaney-indueed hypertension. Journal of Clinical Endocrinology and Metabolism, 1991, 73(3): 489-494.

[3] H. Haller, E. M. Ziegler, V. Homuth, J. Eiehhom, Z. Nagy and F. C. Luft. Endothelial adhesion molecules and leukoeyte integrins in preeclamptic patients. Hypertension, 1997, 29(1 pt 2): 291- 296.

[4] H. Haller, A. Hempel, V. Homuth, A. Mandelkow, C. Maaseh, M. Drab, et al. Endothelial cell permeability and protein kinase C in preeclampsia. Lancet, 1998, 351(9107): 945-949.

[5] G. Wallukat, V. Homuth, T. Fisher, C. Lindsehau, P. B. Horstkam, A. Jupner, et al. Patients with Preeclampsia develop agonistic autoantibodies against the Angiotensin AT1 receptor. Journal of Clinical Investigation, 1999, 103(7): 945-952.

[6] C. A. Hubel. Oxidative stress in the pathogenesis of preeclampsia. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222(3): 222-235.

[7] R. Dechend, C. Viedt, D. N. Muller, B. Ugele, J. Theuer, A. Fiebeler, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation, 2003, 107(12): 1632-1639.

[8] A. Estellés, J. Gilabert, S. Grancha, K. Yamamoto, T. Thinnes, F. España, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Journal of Thrombosis and Haemostasis, 1998, 79(3): 500-508.

[9] R. Dechend, V. Homuth, G. Wallukat, J. Kleuzer, J. K. Park, J. Theuer, et al. AT(l) receptor agonistic antibodies from preeclamptic patient cause vascular cells to express tissue factor. Circulation, 2000, 101(20): 2382-2387.

[10] Y. Xia, H. Y. Wen and R. E. Kellems. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. The Journal of Biological Chemistry, 2002, 277(27): 24601- 24608.

[11] Y. Xia, H. Wen, S. Bobst, M. C. Day and R. E. Kellems. Matemal autoantibodies from Preeclamptic patients activate Angiotensin receptors on human trophoblast cells. Journal of the Society for Gynecologic Investigation, 2003, 10(2): 82-93.

[12] S. M. Bobst, M. C. Day, L. C. Gilstrap, Y. Xia and R. E. Kellems. Maternal autoantibodies from preeclamptic patients activate Angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. American Journal of Hypertension, 2005, 18(3): 330-336.

[13] A. Ahmed. Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Research, 1997, 10: 215-258.

[14] T. Nagamatsu, T. Fujii, M. Kusumi, L. Zou, T. Yamashita, Y. Osuga, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology, 2004, 145(11): 4838-4845.

[15] S. Ahmad, A. Ahmed. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation Research, 2004, 95(9): 884-891.

[16] Y. Zhou, M. McMaster, K. Woo, M. Janatpour, J. Perry, T. Karpanen, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. American Journal of Pa-thology, 2002, 160(4): 1405-1423.

[17] G. C. McKeeman, J. E. Ardill, C. M. Caldwell, A. J. Hunter and N. McClure. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. American Journal of Obstetrics & Gynecology, 2004, 191(4): 1240-1246.

[18] E. D. Dimitrakova, J. D. Dimitrakov, S. A. Karumanchi, B. K. Pehlivanov, N. P. Milchev and D. I. Dimitrakov. Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Medica (Plovdiv), 2004, 46(1): 19-21.

[19] S. E. Maynard, J. Y. Min, J. Merchan, K. H. Lim, J. Li, S. Mondal, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 2003, 111(5): 649-658.

[20] R. J. Levine, R. Thadhani, C. Qian, C. Lam, K. H. Lim, K. F. Yu, et al. Urinary placental growth factor and risk of preeclampsia. Journal of the American Medical Association, 2005, 293(1): 77- 85.

[21] R. J. Levine, S. E. Maynard, C. Qian and K. H. Lim. Circulating Angiogenic factors and the risk of preeclampsia. The New England Journal of Medicine, 2004, 350(7): 672-683.

[22] K. Koga, Y. Osuga, O. Yoshino, Y. Hirota, X. Ruimeng, T. Hirata, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(5): 2348-2351.

[23] C. C. Zhou, S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, et al. Angiotensin II Induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circulation Research, 2007, 100(1): 88-95.

[24] C. C. Zhou, Y. Zhang, R. A. Irani, H. Zhang, T. Mi, E. J. Popek, et al. Angiotensin receptor agonistic autoantibodies induce pre- eclampsia in pregnant mice. Nature Medicine, 2008, 14(8): 855- 862.

[25] R. A. Irani, Y. Zhang, C. C. Zhou, S. C. Blackwell, M. J. Hicks, S. M. Ramin, et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension, 2010, 55(5): 1246-1253.

分享
Top